Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients

This publication has 15 references indexed in Scilit:

• Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
  New England Journal of Medicine, 2003
• A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy
  AIDS, 2003
• The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults
  AIDS Research and Human Retroviruses, 2002
• Antiretroviral Therapy for Previously Treated Patients
  New England Journal of Medicine, 2001
• Human Immunodeficiency Virus Type 1 Entry Inhibitors PRO 542 and T‐20 Are Potently Synergistic in Blocking Virus‐Cell and Cell‐Cell Fusion
  The Journal of Infectious Diseases, 2001
• Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients
  AIDS, 2000
• HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy
  AIDS, 1999
• Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry
  Nature Medicine, 1998
• Antiretroviral Drug Resistance Testing in Adults With HIV Infection
  JAMA, 1998
• Molecular Targets for AIDS Therapy
  Science, 1990